Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines
J. Clin. Invest. Rachel H. McMahan, et al. 116:2543 doi:10.1172/JCI26936 [
Go to this article.]
Figure 3Vaccination with mimotopes of intermediate affinity most effectively protects against tumor challenge. BALB/c mice were primed on days –17 and –10 with (
A) 0 or 0.1 μg, (
B) 1 μg, (
C) 10 μg, or (
D) 100 μg peptides and LANAC (adjuvant) or LANAC alone followed by injection of 5 × 10
4 CT26 tumor cells on day 0 (subcutaneous, back left flank). Tumor-free survival was monitored and plotted using the Kaplan-Meier method (Prism, version 4.0; GraphPad Software). Survival among groups was compared using the log-rank test (Prism, version 4.0; GraphPad Software). *
P < 0.004, **
P < 0.006 versus mimotope 15. All vaccination groups consisted of 8 mice per peptide with the exception of the 10 μg dose, for which 16 mice per peptide were challenged (except for the mimotope 27, 75, and 87 groups, which each consisted of 12 mice).
